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Abstract 
 
The cytotoxic effect of the natural porphyrin precursor 5-aminolevulinic acid (ALA) exposed to 
high energy shock waves (HESW) was investigated in vitro on DHD/K12/TRb rat colon cancer 
cells and in vivo on a syngeneic colon cancer model.  
 
In vitro, viable cell growth was determined by trypan blue exclusion assay and cell death was 
investigated by flow cytometry. ALA (50 µg/ml) and HESW (E1, EFD = 0.22 mJ/mm2, 1000 shots 
or E2, EFD = 0.88 mJ/mm2, 500 shots) showed a significant reduction of cancer cell proliferation at 
day 3 compared to cells exposed to ALA (p<0.01) or HESW (p<0.001) alone. An enhancement of 
necrotic and apoptotic cells was observed after combined treatment at day 1 with ALA and HESW 
E1 (a 3.1 and 6.4 fold increase vs ALA alone) or E2 (a 3.4 and 5.3 fold increase vs ALA alone). 
 
In vivo, apoptosis detection was carried out by TUNEL assay, the pro-apoptotic gene Bad and Bcl-2 
mRNA expression was evaluated by quantitative SYBR Green real time RT-PCR and cleavage of 
poly(ADP-ribose)-polymerase (PARP) was investigated by Western Blotting. An enhancement of 
apoptosis was observed in tumour tissues after the combined treatment at day 1 with ALA (375 
mg/kg i.v.) and HESW (E2) compared to that of ALA exposure alone with improved apoptotic 
index (a 2.0 fold increase), Bad enhanced mRNA expression (p<0.01), Bcl-2 decreased mRNA 
expression (p<0.05) and increased PARP cleavage. The interaction between HESW and ALA is 
then effective in inducing apoptosis on a syngeneic colon cancer model. 
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Introduction 
 
The natural porphyrin precursor 5-aminolevulinic acid (ALA) enters the endogenous heme 
synthesis pathway, the final step of which occurs in the mitochondria and involves the incorporation 
of Fe2+ into protoporphyrin IX (PPIX) to produce heme (1). In normal cells, PPIX, a substance with 
excellent photosensitizing properties, does not accumulate to a great extent because it is quickly 
transformed to heme by the ferrochelatase action of Heme, which is photodynamically inactive. It  
then undergoes rapid degeneration by heme oxygenase. However, in cancer cells, PPIX 
accumulates due to a defective heme biosynthesis, hypothesised to be a result of  abnormal levels of 
some of the enzymes involved in this pathway, especially since increased activity of 
porphobilinogen deaminase and/or decreased activity of ferrochelatase has been reported for a 
number of tumours (2,3). The exogenous application of ALA may then lead to a pronounced 
accumulation of PPIX in tumour tissue and subsequent irradiation with light of wavelengths 
corresponding to the PPIX absorption bands can lead to specific destruction of tumour cells (4).  
 
Although the last 25 years have witnessed the advent of photodynamic therapy (PDT) as an 
innovative clinical cancer treatment modality  the shallow penetration of light through the skin and 
tissues limits PDT to the treatment of superficial endoscopically reachable tumours (5). 
Sonodynamic therapy is an analogous approach, based on the synergistic effect of ultrasound and 
chemical compounds, known as “sonosensitizer”. However, the attractive feature of this modality 
for cancer treatment emerges from the ability to focus the ultrasound energy on malignancy sites 
lying deeply within tissues (6). It has already been reported that high energy shock waves (HESW) 
generated by a piezoelectric device induce acoustic cavitation, which results in a concentration of 
energy that suffices to generate a sonoluminescence emission, able to elicit electronic excitation of 
porphyrins by energy transfer and initiate a photochemical process leading to the formation of the 
cytotoxic singlet oxygen (6,7).  
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Several studies have been conducted in vitro and in vivo to investigate the cytotoxic effect of the 
combination of hematoporphyrin, the most common photodynamic sensitizer and ultrasounds, with 
encouraging results (8-12). Although ALA and HESW has been reported to be effective in vitro 
against a wide range of cancer cell lines (6,13,14), few studies have been conducted in in vivo 
models (6,10). Therefore, this study has attempted to elucidate the possible efficacy of ALA and 
HESW treatment in vivo and for this purpose, various aspects related to apoptosis have been 
examined in a BD-IX rat colon cancer model. 
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Materials and Methods 
 
Cell culture  
The rat colon carcinoma cell line, DHD/K12/TRb (PROb), was obtained from the European 
Collection of Cell Cultures (ECACC, Salisbury, UK). The DHD/K12 cell line is an established 
transplantable carcinoma cell line, originating from a 1,2-dimethylhydralazine-induced colon 
adenocarcinoma in BD-IX rats (15). The subline PROb causes progressive tumours in syngeneic 
rats when inoculated (16). Cells were maintained in culture in Dulbecco's modified Eagle's medium 
(DMEM, Sigma, St Louis, MO, USA) supplemented with 10% heat-inactivated fetal calf serum 
(FCS), 2 mM L-glutamine, 100 UI/ml penicillin, 100 µg/ml streptomycin (Sigma) and at 37 °C in a 
humidified atmosphere of 5% CO2-air. 
 
In vitro shock wave exposure  
A piezoelectric shock wave generator (Piezoson 100, Richard Wolf, Knittlingen, Germany), 
provided by Med & Sport 2000 S.r.l., Torino, Italy was used for the study. This device generates 
focused underwater shock waves at various frequencies (1–4 shocks/s) and intensities (0.05–1.48 
mJ/mm2). The energy at the focal point is defined as energy flux density (EFD) per impulse, 
recorded as joules per area (mJ/mm2) (17). The axial and lateral dimensions are used to calculate 
the volume of the focus, simplified under the assumption of an elliptical focus ‘cigar’ where the 
long axis lies in the direction of the shock wave propagation. The focus volume is defined as the 
zone where 50% of the maximum energy is delivered (18).  As to the Piezoson 100, the focus zone 
has a length of 10 mm in the direction of the axis of the shock wave propagation and a diameter of 
2.5 mm perpendicular to this axis.  
 
Aliquots of 1 ml of cell suspension adjusted to 1×106 cell/ml were placed into 2 ml polypropylene 
tubes (Corning, New York, USA), which were then completely filled with culture medium, for the 
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in vitro experiments. Subsequently, cells were gently pelleted by centrifugation at 250g, so as to 
minimize motion during shock wave treatment. The experimental set-up was carried out as 
previously described (19). Two HESW treatment schedules were then investigated: E1, 
characterized by an EFD of 0.22 mJ/mm2 and a peak positive pressure of 31 MPa (1000 shots; 
frequency: 4 shocks/s) and E2, characterized by an EFD of 0.88 mJ/mm2 and a peak positive 
pressure of 90 MPa (500 shots; frequency: 4 shocks/s).  
 
In vitro 5-aminolevulinic acid exposure 
DHD/K12/TRb cells in the exponential growth phase were preincubated in DMEM, supplemented 
with 1% FCS containing ALA (10-100 µg/ml) (Sigma, St Louis, MO, USA) for 24 h, then removed 
from the flask with 0.05% trypsin-0.02% EDTA solution and normalized to 1x106 cells. The 
intracellular fluorescence, determined by the photodynamical active substance PPIX, after cell 
exposure to the precursor ALA, was evaluated by flow cytometer so as to establish the most 
suitable concentration for the study (i.e. the concentration reaching over 50% of cell population 
without significantly affecting cell viability). Control and ALA-treated (50 µg/ml) cells were then 
exposed to HESW treatment, as described above. 
 
In vitro protocol 
To determine cell viability, control cells (i.e. cells receiving no ALA or HESW treatment), cells 
treated with ALA (i.e. preincubated with ALA 50 µg/ml for 24 h), cells treated with HESW (E1, 
EFD = 0.22 mJ/mm2, 1000 shots; and E2, EFD = 0.88 mJ/mm2, 500 shots) and their combination, 
were normalized at 25,000 cells/ml, seeded in 24 well/plate in DMEM medium with 10% FCS and 
subcultured in standard culture conditions for 7 consecutive days. At days 1, 3 and 7, cells were 
detached with trypsin/EDTA and viable cell growth was determined by trypan blue die exclusion. 
Viability was expressed as percentage of control cells. Cell viability assay was performed in 
triplicate. 
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To analyses cell death, DHD/K12/TRb cells were handled and treated according to the protocol laid 
out in the Annexin-V-Fluorescin (A-V-FITC) Apoptosis Detection Kit (Sigma). The cells (1x106 
cells/ml), whether preincubated or not with ALA 50 µg/ml for 24 h, were exposed to HESW (E1, 
EFD = 0.22 mJ/mm2, 1000 shots and E2, EFD = 0.88 mJ/mm2, 500 shots) and washed once with 
PBS to be re-suspended in a binding buffer. A 500 µl aliquot of cell suspension was protected from 
light and stained with 5 µl of A-V-FITC and 10 µl of propidium iodide (PI) in a 12x75 mm test tube 
(Corning, New York, USA) for 10 min at room temperature. The cells were then analysed using an 
EPICS XL flow cytometer (Coulter Corp., Hialeah, FL, USA) by counting 10,000 events. Viable 
cells were defined as A-V-FITC and PI negative. Cell death analysis was performed in triplicate. 
 
In vivo shock wave exposure  
The same piezoelectric shock wave generator used for in vitro experiments was employed for the in 
vivo experiments. Tumour bearing rats were anesthetized with an intraperitoneal injection of 
zolazepam (50 mg/kg) (Zoletil®, Virbac Laboratories) on week 8 after DHD/K12/TRb inoculation. 
The animals treated with HESW E2 (0.88 mJ/mm2, 500 shots) were fixed to a board in a supine 
position, the abdomen shaved and ultrasound gel applied to the naked skin. The transducer was then  
placed in close contact with the tumour. Following sonographic prelocation, the position and  angle 
of the transducer were adjusted to locate the tumour at the focal spot, thus allowing for focused 
shock waves to propagate throughout the cancer. All animals were placed on a warm blanket and 
observed until their complete recovery, before being put back into their cages. 
 
Animals treated with ALA, or on the combination treatment, were given an i.v. injection of ALA 
before being exposed to the HESW. All animals were sacrificed 24 h after the HESW in vivo 
session and primary tumours were removed, weighed and stored in 10% buffered formalin for 
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histological examination, in RNAlater (Sigma) for RNA isolation and in TRI Reagent (Sigma) for 
protein isolation. 
 
In vivo protocol 
Syngeneic adult BD-IX male rats, weighing 200 to 250 g, were obtained from Charles River Italia 
(Milano, Italy). The animals were housed in temperature- and humidity-controlled rooms with a 12 
h light/dark cycle and allowed free access to food and water. They were handled according to 
European guidelines (Directive CEE 86/609) and the experimental protocol was reviewed and 
approved by the Animal Ethic Committee of the University of Torino, Italy.  
 
Before inoculation, DHD/K12/TRb cells, grown in serum-containing medium, were washed with 
Hank’s balanced buffer and centrifuged at 1500 rpm for 5 min. Cell pellets (1x106 cells) were re-
suspended in 0.15 ml of phosphate-buffered saline (PBS). Each animal was weighed and 
anaesthetized with an intraperitoneal injection of zolazepam (50 mg/kg) (Zoletil®, Virbac 
Laboratories, Carros, France). A laparotomy of 2 cm on average was then performed and the 
caecum isolated. An intramural injection of 1x106 cells in 0.15 ml of PBS was given in the caecum 
0.5 cm through the iliocaecal valve.  
 
Eight weeks after cancer cell implantation, the animals were randomly assigned to four treatment 
groups, with at least four animals per group. Control and experimental animals were treated with 
one single saline i.v. injection into the tail vein, a single ALA i.v. injection into the tail vein (375 
mg/kg), HESW E2 (0.88 mJ/mm2, 500 shots) or a combination of ALA and HESW E2 (375 mg/kg 
+ 0.88 mJ/mm2, 500 shots). ALA was dissolved in PBS at a concentration of 80 mg/ml. This 
solution was injected into a tail vein 3 h before HESW treatment, resulting  in a ALA dose of 375 
mg/kg (total injection volume per rat approximately 1 ml). An equivalent volume of PBS was 
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administered to the control animals. The ALA dose used was selected on the basis of the one which 
showed the  greatest inhibitory effect on tumour growth concurrent with low general toxicity (4). 
 
All control and experimental animals were sacrificed 24 h post HESW treatment, examined and 
scored for the development of macroscopic tumour metastases in various tissues. Primary tumour 
tissues were then removed for histological examination. The tumour masses of both control and 
experimental animals were measured in two dimensions by callipers and the tumour volume (V) 
was calculated by the formula V=4/3πr3, r being the mean of the two orthogonal radii. 
 
Haematoxylin-eosin staining and TUNEL analysis 
After extensive washing, the fixed tissue fragments were dehydrated through a graded series of 
ethanol solutions and then passed in xylene and embedded in paraffin before making histological 
sections. Specimens (4 µm) were washed in xylene and dehydrated according to standard protocols. 
Sections were either stained with haematoxylin-eosin, or used for terminal 
deoxynucleotidyltransferase-mediated dUTP nick end labelling (TUNEL), which was carried out 
using the In Situ Cell Death Detection Kit, POD, (Roche, Indianapolis, USA) according to the 
manufacturer's instructions.   
 
Briefly, the sections were deparaffinized and the samples  pre-treated with 20 µg/ml proteinase K 
(Roche) for 25 min at 37°C and incubated with TUNEL reaction mixture (terminal 
deoxynucleotidyl transferase, FITC-labelled nucleotides) for 1 h and covered with peroxidase 
conjugated anti-fluorescein antibody for 30 min at 37°C. The substrate colour reaction applying 
chromogen DAB (3,3’-diaminobenzidine tetrahydrochloride) (Roche) was added to the samples for 
10 min. Endogenous peroxidase activity was blocked by incubation with 1.3% H2O2 in PBS for 10 
min at room temperature, before enzymatic labelling. All slides were counter-stained using Meyer 
haematoxylin.  
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The classical morphological apoptosis criteria of nuclear condensation, membrane blebbing and the 
formation of apoptotic bodies, combined with TUNEL-positive reaction of the nuclei, were used to 
evaluate apoptosis by light microscopy. The apoptotic index was expressed as a percentage of 
TUNEL-positive cells per total counted cells in random fields, with a minimum of five fields 
counted per slide, at 40x magnification. 
 
RNA isolation and SYBR Green real time RT-PCR 
The RNA was isolated by homogenising tumour samples which were then directly subjected to total 
RNA isolation by TRI Reagent (Sigma), according to the manufacture’s instructions. The RNA 
concentrations were measured at spectophotometry at 260 and 280 nm with correction for 
background, at 300 nm. The integrity of the RNA was confirmed by assessing the clarity of the 
ribosomal bands on ethidium-stained agarose. QuantiTect Primer Assay (Qiagen, Milano, Italy) was 
used as the gene-specific primer pair for BAD (Cat. No. QT00190407) and BCL-2 (Cat. No. 
QT00184863). Quantitative RT-PCR was performed using the QuantiTect SYBR Green RT-PCR 
Kit (Qiagen). Real-time RT-PCR analysis was carried out using 1 µg of total RNA, which was 
reverse transcribed in a 20 µl complementary deoxyribonucleic acid (cDNA) reaction using the 
QuantiTect Reverse Transcription Kit (Qiagen), 100 ng of cDNA was used for each 25 µl real-time 
RT-PCR reaction. 
 
The housekeeping GAPDH (Cat. No. QT00199633) gene transcript and real-time PCR was 
performed by an iQ5 real-time PCR detection system (BIO-RAD, Milano, Italy) to normalise 
mRNA data. The PCR protocol conditions were as follows: HotStarTaq DNA polymerase 
activation step at 95°C for 15 min, followed by 40 cycles at various temperatures/times: i.e. 94°C 
for 15 sec, 55°C for 30 sec and  72°C for 30 sec. All samples were run in duplicate. At least two 
non-template controls were included in all PCR runs. At the end of the PCR, baseline and threshold 
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values (CT) for BAD, BCL-2 and GAPDH  were set using the iQ5 real-time PCR Software and the 
calculated CT values were exported to Microsoft Excel for analysis. The relative expression of BAD 
and BCL-2 mRNA was calculated using the comparative CT method, according to the 
manufacturer’s literature (BIO-RAD).  
 
The relative amount of BAD and BCL-2 mRNA, standardised against the amount of GAPDH 
mRNA, in tissues was expressed as -ΔCT=[CT BAD/BCL-2-CT GAPDH]. The ratio of BAD or BCL-2 
mRNA/GAPDH mRNA, i.e. the relative BAD or BCL-2 expression, was then calculated as 2-ΔCT. 
The independent t test was used to analyse the differences of BAD and BCL-2 mRNA expression in 
the various groups.  
 
PARP cleavage assay 
Proteins were isolated by homogenising tumour samples, which were then directly subjected to total 
protein isolation by TRI Reagent (Sigma), according to the manufacture’s instructions. The protein 
concentrations were measured by the Bradford assay. Poly(ADP-ribose)-polymerase (PARP) 
cleavage were analyzed by immunoblotting. Proteins were subjected to SDS-PAGE (NuPAGE, 
Invitrogen) and electroblotted to a nitrocellulose membrane (Sigma). Membrane was probed with 
the following primary antibody: rabbit polyclonal antibody anti-poly-(ADP-ribose)-polymerase 
(Sigma). Intact and cleaved PARP (116 and 89 kDa, respectively) were detected using ProteoQwest 
Colorimetric Western Blotting Kit with TMB substrate (Sigma) according to the manufacturer’s 
recommendations.  
 
Data analyses 
Data are expressed throughout as mean ± SD. Statistical comparisons between treatment groups 
were performed with analysis of variance (one-way ANOVA) and the threshold of significance was 
calculated by  Bonferroni’s test. Statistical significance was set at p<0.05.  
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Results 
 
In vitro effect on DHD/K12/TRb cells 
As shown in Table I, ALA exposure for 24 h had no effect on DHD/K12/TRb cell viability up to 50 
µg/ml. Moreover, a significant increase in mean cell fluorenscence intensity (MFI) (p<0.001) was 
observed after exposure to ALA at 50 µg/ml and more than 50% of the cell population were able to 
synthesize and accumulate the fluorescent photosensitizer PPIX.  
 
The effect on cell viability after HESW exposure was then evaluated at days 1, 3 and 7, after cell 
exposure to ALA at 50 µg/ml for 24 h. HESW either E1 (EFD = 0.22 mJ/mm2, 1000 shots) or E2 
(EFD = 0.88 mJ/mm2, 500 shots) treatment alone had no effect on DHD/K12/TRb cell viability at 
days 1, 3 or  7. At day 1, ALA treatment alone had no effect on cell viability, while the combined 
treatment (ALA and HESW) led to a significant reduction of DHD/K12/TRb cell viability (p<0.01). 
At day 3, ALA treatment alone effected cell viability (p<0.01) and the combined treatment led to a 
marked reduction in cell viability (p<0.001) (Figure 1). At day 7, a decreased reduction in 
DHD/K12/TRb cell viability after either ALA treatment alone or combined treatment was observed 
(p<0.05 and p<0.01, respectively). 
 
So as to further explore the increasing cytotoxic effect of HESW treatment on ALA treated cells, 
DHD/K12/TRb cell death was evaluated by annexin V/propidium iodide assay at day 1. The HESW 
(E1 and E2), or ALA treatment alone led to a similar percentage of necrotic and apoptotic cells as 
did untreated cells, indicating that ALA or HESW treatment alone did not induce either cell 
necrosis or apoptosis. Conversely there was a significant increase in both necrotic and apoptotic 
cells after the combined ALA and HESW E1 treatment  (36.8 and 42.8%, respectively) or E2 (40.2 
and 35.4%, respectively), compared to the necrotic and apoptotic cell percentage obtained by  
treatment with ALA alone (11.0 and 6.7%, respectively) and HESW E1 (8.4 and 4.6%, 
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respectively) or E2 alone (10.5 and 6.0%, respectively) (Figure 2). Therefore, HESW treatment 
determined a significant enhancement of ALA induced necrosis and apoptosis in DHD/K12/TRb 
cells. 
 
In vivo effect on DHD/K12/TRb tumours 
Eight weeks after DHD/K12/TRb cell inoculation, animals in the control group were treated with 
one single saline i.v. injection into the tail vein, whereas the experimental animal group was treated 
with a single ALA i.v. injection into the tail vein (375 mg/kg, 3 h before shock wave exposure), 
HESW E2 (0.88 mJ/mm2, 500 shots) or an ALA and HESW combination treatment. The cytotoxic 
effect of the treatments was evaluated by measuring the percentage of apoptotic cells in the 
DHD/K12/TRb tumours with nuclear fragment DNA staining, using the TUNEL method and 
histological examination of haematoxylin-eosin stained sections at 24 h post-HESW treatment. 
The tumour volume averaged 2923±97 mm3 and the mean tumour volume did not differ 
significantly from that of  the control animals. 
 
The TUNEL analysis showed that the combined ALA HESW treatment induced a significant 
increase in the apoptotic index (6.9 ± 1.1%) versus the control group (1.8 ±0.2%; p<0.01), the 
HESW group (3.7 ± 0.5%; p<0.01) and versus the ALA group (3.9 ± 0.7%; p<0.05) (Figure 3). 
Conversely, neither ALA nor HESW treatment alone produced a significant change in the apoptotic 
index of cancerous cells versus the control group. As already observed in in vitro experiments, 
HESW treatment may trigger ALA cytotoxicity in colon cancer tumour. Histological examination 
of the haematoxylin-eosin sections from ALA + HESW treated animals showed larger areas of 
tumour necrosis, confirming the  TUNEL analysis findings (Figure 4).  
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In vivo effect on apoptotic gene expression 
Real time RT-PCR analysis was used to confirm the apoptotic pathways expressed by the TUNEL 
analysis, investigating the mRNA expression of the pro-apoptotic BAD and anti-apoptotic BCL-2 
gene involved in the apoptotic machinery. Figure 5 shows that mRNA expression of BAD was 
enhanced whilst the mRNA expression of BCL-2 was lower in the animals treated with ALA and 
HESW compared to the control animals (p<0.05). When a comparison was made with the control 
group, it was observed that, in the ALA and HESW treated group, the BAD mRNA steady-state 
level was up-regulated, with 2.4 fold increase, whilst the BCL-2 mRNA steady-state level was 
down-regulated with 4.5 fold decrease. As shown in Figure 5, in the ALA and HESW group versus 
the ALA group, the BAD mRNA steady-state level was also up-regulated, with a 2.0 fold increase, 
whilst the BCL-2 mRNA steady-state level was down-regulated with a 2.0 fold decrease.  
 
In vivo effect on PARP cleavage 
Western Blotting was used to check whether DHD/K12/TRb tumours in BD-IX rats exposed to 
ALA (375 mg/kg, i.v.) or/and HESW E2 (0.88 mJ/mm2, 500 shots) treatment express any hallmarks 
of the apoptotic process i.e. specific cleavage of PARP into 89 kDa fragment, as marker of 
activation of caspases. At 24 h post-treatment, PARP cleavage was evident after ALA treatment 
alone in only one of the four tumour tissues exposed, likewise after HESW E2 treatment alone and 
in three of the four tumour tissues exposed after the combined treatment with ALA and HESW E2 
(Figure 6).  
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Discussion 
 
Sonodynamic therapy has been suggested as an innovative modality for cancer treatment, as it is 
able to enhance the cytotoxic activities of compounds defined as sonosensitizers. The main 
assumption about the sonodynamic therapy is to generate ultrasound energy which produces 
sonoluminescence to excite the hematoporphyrin derivative by energy transfer. This initiates a 
photochemical process which leads to the formation of the cytotoxic singlet oxygen (20).  
 
Shock waves can propagate through different substances without significant energy dissipation as 
long as  the acoustic impedance values of the substances are similar. Because of the similarity in the 
acoustic impedance values of water and the soft tissues of the body, shock waves can be transmitted 
through these tissues without any substantial energy loss. However, at transition sites between 
tissues with different acoustic impedance values, energy dissipation occurs and there may be focal 
mechanical destruction, probably produced through the induction of cavitation and shearing stress 
caused by the reflected waves (21).  
 
In a previous study we investigated  in a human colon cancer cell line, HT-29, which was exposed 
to ALA, the effects a piezoelectric device able to generate pulse HESW with two basic effects: the 
direct generation of mechanical forces (non-inertial cavitation) and the indirect generation of 
mechanical forces by cavitation (inertial cavitation). Non-inertial cavitation bubbles oscillate about 
an equilibrium radius and often persist through many acoustic cycles. These oscillations cause 
streaming of the surrounding liquid and mechanical stresses to create a mixing of the medium. 
Inertial cavitation is an extremely violent process of bubble activity that may lead to pyrolysis of the 
water vapour inside the bubble, generating highly reactive hydroxyl radical and hydrogen atoms. 
Inertial cavitation can also be followed by energy transfer to oxygen to generate the highly reactive 
singlet molecular oxygen (6). 
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This mix between inertial and non-inertial cavitation, generated by our piezoelectric device, was 
confirmed in our previous study (13), where we demonstrated that combined ALA HESW treatment 
produced significant inhibition of HT-29 cell growth, where non-inertial cavitation and inertial 
cavitation were seen to induce apoptosis and inhibit cell growth by increasing the G0/G1 population 
through the intracellular activation of protoporphyrin IX.  
 
So as to further our investigation we evaluated the effect of HESW on DHD/K12/TRb rat colon 
cancer cells previously exposed to ALA, a natural porphyrin precursor commonly used as 
sonosensitizer, in a syngeneic model of colon cancer. Our results show that DHD/K12/TRb cells are 
sensitive to ALA and HESW treatment. The fact that the piezoelectric device used is able to 
generate  different combinations of the two basic effects suggests that HESW E1 and E2 schedules 
represented  a dissimilar mechanism involved in the synergism between ultrasounds and ALA. 
 
ALA exposed to HESW led to a significant reduction of in vitro cancer cell proliferation at day 3 
compared to cells exposed to ALA (p<0.01), or HESW (p<0.001) alone. An enhancement of 
necrotic and apoptotic cells was observed after the combined treatment with ALA and HESW E1 
(3.1 and 6.4 fold increase vs ALA alone), or E2 (3.4 and 5.3 fold increase vs ALA alone). These 
findings are in agreement with our previous reports, indicating that shock waves have a sudden 
effect in enhancing cytotoxic activities of compounds defined as sonosensitizers in different cell 
lines (13,14). 
 
In the BD-IX rat colon cancer model, a significant increase in the apoptotic index of DHD/K12/TRb 
tumours exposed to the combined treatment compared to controls, HESW and ALA alone was 
observed by the TUNEL method (Figure 3). Moreover, we investigated the pro-apoptotic gene 
BAD and anti-apoptotic gene BCL-2 mRNA expression in an effort to better understand the 
apoptotic pathways triggered. A Bad enhanced mRNA expression (p<0.01) and Bcl-2 decreased 
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mRNA expression (p<0.05) was observed in the group exposed to HESW in combination with 
ALA, compared to that observed with single treatment alone (i.e. ALA or HESW E2) ( Figure 5). 
 
PARP is a chromatin-associated enzyme which, in response to DNA damage, binds to DNA strand 
breaks and undergoes automodification by forming long, branched poly (ADP) ribose polymers 
(22). In this study, an enhanced PARP cleavage was observed in tumour tissues exposed to the 
combined treatment compared to those exposed to the single treatment alone (i.e. ALA or HESW), 
thus confirming that HESW are able to activate ALA. 
 
These data confirm that combined ALA and HESW treatment suppresses cell proliferation and is 
able to induce apoptosis not only in vitro, but also in solid in vivo tumours. This finding is also in 
keeping with results reported by Canaparo et al in a syngeneic rat model of breast cancer and by 
Maruyama et al in a mouse hepatoma model (23,24). Several distinct sonochemical effects were 
observed after sonodynamic treatment with ultrasound in various cell lines, including changes in 
cell viability, the generation of mitochondrial ROS, mitochondrial swelling and the release of 
cytochrome c, showing that the ultrasonically-induced cell-killing effect could be enhanced by 
PPIX (25,26). Moreover, the usefulness of sonodynamic therapy, taking advantage of focused 
ultrasound and photosensitizer was evidenced in the treatment of experimental sarcoma and 
malignant glioma (27,28). 
 
In conclusion, HESW might be proposed for the sonodynamic treatment of cancer since the 
interaction between focused ultrasonic fields and a photosensitizer like ALA is effective in inducing 
apoptosis in tumours cells. Anyhow, further experiments are needed to support our hypotesis that 
HESW are able to produce in vivo sonoluminescence since we do not have evidence about light 
emission associated with cavitation mechanism in our syngeneic model of colon cancer.  
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Table I 
 
5-aminolevulinic acid (ALA) effect on mean fluorescence intensity (MFI) and viability of 
DHD/K12/TRb cells after 24 h exposure 
 
 
 
Significance versus ALA unexposed cells: * p<0.05, ** p<0.01; *** p<0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
MFI Ratio Fluorescent Cells Viability Ratio
Ala treated cells/ 
Control cells Percentage
Ala treated cells/ 
Control cells
ALA 25 µg/ml   2.4 **     37.6 *** 1.0
ALA 50 µg/ml     3.6 ***     57.6 *** 1.0
ALA 100 µg/ml     5.8 ***     70.2 ***     0.8 *
Condition
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Figure Legends 
 
Figure 1 
In vitro effect of ALA (50 µg/ml) and HESW (E1, EFD = 0.22 mJ/mm2, 1000 shots; E2, EFD = 
0.88 mJ/mm2, 500 shots) on DHD/K12/TRb cells at day 1, 3 and 7. Cell viability is determined as 
the ratio between treated cells and untreated control cells (100%). The results are expressed as mean 
values ± SD of three independent experiments. Significance versus control cells: * p<0.05, ** 
p<0.01, *** p<0.001; versus cells exposed to ALA alone: ° p<0.05, °° p<0.01, °°° p<0.001. 
 
Figure 2 
In vitro cell necrosis and apoptosis with ALA (50 µg/ml) and HESW (E1, EFD = 0.22 mJ/mm2, 
1000 shots; E2, EFD = 0.88 mJ/mm2, 500 shots) in DHD/K12/TRb cells at day 1. Data are 
presented as a percentage of cells in the necrotic or apoptotic state and are mean values ± SD of 
three independent experiments. Significance versus control cells: *** p<0.001. 
 
Figure 3 
The morphologic features of the cells in control (a), ALA (375 mg/kg i.v. injection) (b), HESW 
(E2, 0.88 mJ/mm2, 500 shots) (c) and combined treatment (ALA + HESW) groups (d). 
Representative haematoxylin-eosin sections of each group are shown. 
The haematoxylin-eosin staining DHD/K12/TRb tumours at 24 h after treatment were examined 
and photographed under light microscope at a 10x magnification. 
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Figure 4 
In vivo effect of ALA (375 mg/kg i.v. injection) and HESW (E2, 0.88 mJ/mm2, 500 shots) on 
DHD/K12/TRb tumours in BD-IX rats at 24 h after combined treatment. Data are presented as 
apoptotic index determined by the TUNEL analysis as percentage of apoptotic cells per total 
counted cells in random fields. The results are mean values ± SD. Significance versus control cells: 
** p<0.01; versus cells exposed to ALA alone: ° p<0.05 
 
Figure 5 
In vivo effect of ALA (375 mg/kg i.v. injection) and HESW (E2, 0.88 mJ/mm2, 500 shots) on BAD 
and BCL-2 mRNA expression in DHD/K12/TRb tumours in BD-IX rats at 24 h after combined 
treatment by real time RT-PCR. The different transcript level normalized to those of GAPDH 
mRNA expression. Significance versus control cells: * p<0.05. 
 
Figure 6 
In vivo effect of ALA (375 mg/kg i.v. injection) and HESW (E2, 0.88 mJ/mm2, 500 shots) on PARP 
cleavage induction in DHD/K12/TRb tumours in BD-IX rats at 24 h after combined treatment. 
Protein extracts were subjected to 10% SDS-PAGE and PARP cleavage was assessed by Western 
Blotting with an anti-PARP antibody (1:1500) which detects intact (116 kDa) and cleaved (89 kDa) 
products. 
 
